Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Status Completed

Clinical Trial Summary

Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis

Clinical Trial Description

The study drug is Isoniazid formulated with HUEXC030 as excipient for eradicating ATDH, whereas the reference control is Isoniazid formulated with inactive excipient. Subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study. Eligible subjects will be randomized in a 1:1 ratio to receive study drug or reference control drug. Subjects will be genotyped according to a selected panel of single nucleotide polymorphisms (SNPs) and categorized into high risk or low risk groups for occurring ATDH via a specific haplotype consists of CYP2E1 and NAT2 SNPs. Based on an extensive study result during 2007 to 2011,the estimated frequency for patients bearing high risk genotypes in Taiwanese population is around 25%. Approximately 352 subjects will be enrolled for genotype screening in order to recruit 88 high risk subjects for each of 44 subjects in the intervention and control arms. Subjects who are stratified as high risk groups will be administered the test drug or reference control drugs oral daily for 6 months or until treatment completion, i.e. bacteriologically confirmed negative of active M. tuberculosis. Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication under the care of their investigator for at least one follow-up visit at 4 weeks after the End of Study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02467608
Study type	Interventional
Source	Orient Pharma Co., Ltd.
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	December 6, 2012
Completion date	January 9, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02736864` - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae	N/A
Not yet recruiting	`NCT04055441` - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed	`NCT02349841` - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis	Phase 2
Completed	`NCT01927159` - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers	Phase 1
Active, not recruiting	`NCT01691534` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)	Phase 2
Completed	`NCT00803322` - Improving Community Based Tuberculosis Care in Ethiopia	Phase 4
Completed	`NCT00834353` - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis	N/A
Withdrawn	`NCT03277742` - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz	N/A
Completed	`NCT00057434` - Vitamin A Therapy for Tuberculosis	Phase 3
Not yet recruiting	`NCT06192160` - Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis	Phase 2
Recruiting	`NCT06127641` - Rehabilitation of People With Post-tuberculosis Lung Disease	N/A
Recruiting	`NCT06058299` - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis	Phase 2
Completed	`NCT04550832` - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)	Phase 2
Completed	`NCT02912832` - Prospective Assessment of TBDx Feasibility	N/A
Completed	`NCT01215851` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)	Phase 2
Recruiting	`NCT01503099` - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease	N/A
Completed	`NCT04608955` - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081	Phase 2
Recruiting	`NCT05046366` - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed	`NCT05896930` - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis	Phase 2
Completed	`NCT02279875` - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)	Phase 2